Literature DB >> 21840651

Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers.

James P Zacny1, Judith A Paice, Dennis W Coalson.   

Abstract

BACKGROUND: Some chronic pain patients on long-term opioid therapy also take centrally active skeletal muscle relaxants. One of those muscle relaxants is carisoprodol, a drug that is abused and capable of producing impairment. It would be of relevance to characterize the effects of an opioid and carisoprodol when taken together to determine if abuse liability-related measures and psychomotor impairment are increased compared to when the drugs are taken alone.
METHODS: As part of a larger crossover, randomized, double-blind study, we examined the subjective and psychomotor responses of 15 healthy volunteers to four experimental conditions: placebo, 350 mg carisoprodol, 10mg oxycodone, and 350 mg carisoprodol followed 60 min later by 10mg oxycodone (intended to test the interaction of the two drugs when they were producing their maximal effects).
RESULTS: Preliminary data analyses indicated that some of carisoprodol's effects were declining when we tested for drug interactions. Despite this, on some outcome measures in which the drugs alone did not differ from placebo, when tested together subjective effects were increased, including those that were abuse liability-related, and psychomotor performance decreased, relative to placebo.
CONCLUSIONS: This is the first study that we are aware of that has shown that carisoprodol and oxycodone, two drugs that are sometimes co-prescribed for relief of pain, produce effects when administered "together" (i.e., separated by 60 min) that are of greater magnitude than when they are administered alone. Some of the effects were not benign, and are of concern from both abuse liability and public safety standpoints.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840651      PMCID: PMC3240720          DOI: 10.1016/j.drugalcdep.2011.07.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  16 in total

1.  Possible dangerous interaction of oxycontin and carisoprodol.

Authors:  Roy R Reeves; James E Mack
Journal:  Am Fam Physician       Date:  2003-03-01       Impact factor: 3.292

2.  The prevalence of chronic pain in United States adults: results of an Internet-based survey.

Authors:  Catherine B Johannes; T Kim Le; Xiaolei Zhou; Joseph A Johnston; Robert H Dworkin
Journal:  J Pain       Date:  2010-08-25       Impact factor: 5.820

3.  Abuse of combinations of carisoprodol and tramadol.

Authors:  R R Reeves; V Liberto
Journal:  South Med J       Date:  2001-05       Impact factor: 0.954

4.  The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Margaretha Gulliksen; Harald Breilid; Vidar M Steen; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

Review 5.  Carisoprodol legal status and patterns of abuse.

Authors:  Jennifer A Fass
Journal:  Ann Pharmacother       Date:  2010-11-09       Impact factor: 3.154

6.  Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Charles Dillon; Ryne Paulose-Ram; Rosemarie Hirsch; Qiuping Gu
Journal:  Spine (Phila Pa 1976)       Date:  2004-04-15       Impact factor: 3.468

Review 7.  Carisoprodol: abuse potential and withdrawal syndrome.

Authors:  Roy R Reeves; Randy S Burke
Journal:  Curr Drug Abuse Rev       Date:  2010-03

8.  Impairment due to intake of carisoprodol.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland
Journal:  Drug Alcohol Depend       Date:  2004-06-11       Impact factor: 4.492

9.  The risk of traffic accidents after prescriptions of carisoprodol.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland; Anders Engeland
Journal:  Accid Anal Prev       Date:  2007-03-23

10.  Clinical characteristics of chronic back pain as a function of gender and oral opioid use.

Authors:  Roger B Fillingim; Daniel M Doleys; Robert R Edwards; Daniel Lowery
Journal:  Spine (Phila Pa 1976)       Date:  2003-01-15       Impact factor: 3.468

View more
  7 in total

1.  Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.

Authors:  Manish Kumar; Glenn H Dillon
Journal:  Eur J Pharmacol       Date:  2016-02-09       Impact factor: 4.432

2.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

3.  Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Drug Alcohol Depend       Date:  2012-02-25       Impact factor: 4.492

4.  Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

Authors:  Manoj Kumar; Lorie A González; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2015-04-18       Impact factor: 5.250

Review 5.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

6.  Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort.

Authors:  Jonathan D Dau; MinJae Lee; Michael M Ward; Lianne S Gensler; Matthew A Brown; Thomas J Learch; Laura A Diekman; Amirali Tahanan; Mohammad H Rahbar; Michael H Weisman; John D Reveille
Journal:  J Rheumatol       Date:  2017-12-01       Impact factor: 4.666

7.  Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.

Authors:  Margot A Cousin; Jon O Ebbert; Amanda R Wiinamaki; Mark D Urban; David P Argue; Stephen C Ekker; Eric W Klee
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.